Agios Pharmaceuticals, Inc. - Common Stock (AGIO)

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat), developed by Agios Pharmaceuticals (NASDAQ: AGIO), for the treatment of anemia in adults with alpha- and beta-thalassemia. This milestone marks a pivotal moment for the Cambridge, Massachusetts-based [...]

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

The company received FDA approval for its leading drug, and investors were pleased with the update from management.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia.

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of mixed topline results from its pivotal RISE UP Phase 3 trial for mitapivat in sickle cell disease (SCD). While the investigational therapy

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The company's pivotal Phase 3 trial hit one primary endpoint but missed another.

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, prompting mixed investor reaction.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios said.

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Agios Pharma's Q3 2025 results beat revenue and EPS estimates, driving a positive market reaction and highlighting strong commercial performance.

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential